SSA
EVFM

Schonfeld Strategic Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-28,100
Closed -$32K – 3393
2022
Q2 		$32K Buy
+28,100
New +$46.3K ﹤0.01% 2269

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Schonfeld Strategic Advisors's EVFM Position: Q3 2022 in Review

Schonfeld Strategic Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 28,100 shares — an estimated $32K sold.

Schonfeld Strategic Advisors first reported a position in EVFM in Q2 2022 and held it in 1 quarter. The position peaked at $32K in Q2 2022. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • Schonfeld Strategic Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 28,100 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $32K.
  • Schonfeld Strategic Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $32K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.